The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.

The study reveals that 10% of patients treated with eli-cel developed hematologic cancer, with an incidence rate of 2.1 per 100 person-years. This finding emphasizes the need for careful monitoring and risk assessment in gene therapy approaches.

A Connecticut court’s $17.1 million award in a stillbirth case emphasizes the need for vigilant monitoring and timely intervention in pregnancies complicated by liver conditions.

In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.

Chlamydial proctitis can present with symptoms mimicking other conditions, making a thorough sexual history and appropriate testing essential for accurate diagnosis and treatment.

N=1 science empowers patients to become “citizen scientists,” experimenting and refining their health choices to find what works best for their own bodies.